176 related articles for article (PubMed ID: 23320070)
41. Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial.
Divgi CR; Uzzo RG; Gatsonis C; Bartz R; Treutner S; Yu JQ; Chen D; Carrasquillo JA; Larson S; Bevan P; Russo P
J Clin Oncol; 2013 Jan; 31(2):187-94. PubMed ID: 23213092
[TBL] [Abstract][Full Text] [Related]
42. Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study.
Smits ML; Nijsen JF; van den Bosch MA; Lam MG; Vente MA; Mali WP; van Het Schip AD; Zonnenberg BA
Lancet Oncol; 2012 Oct; 13(10):1025-34. PubMed ID: 22920685
[TBL] [Abstract][Full Text] [Related]
43. Tumour embolization of the Vx2 rabbit head and neck cancer model with Dextran hydrogel and Holmium-poly(L-lactic acid) microspheres: a radionuclide and histological pilot study.
van Es RJ; Nijsen JF; Dullens HF; Kicken M; van der Bilt A; Hennink W; Koole R; Slootweg PJ
J Craniomaxillofac Surg; 2001 Oct; 29(5):289-97. PubMed ID: 11673924
[TBL] [Abstract][Full Text] [Related]
44.
Liu Q; Qian Y; Li P; Zhang S; Liu J; Sun X; Fulham M; Feng D; Huang G; Lu W; Song S
Theranostics; 2018; 8(3):785-799. PubMed ID: 29344306
[No Abstract] [Full Text] [Related]
45. Chemoradiotherapeutic Magnetic Nanoparticles for Targeted Treatment of Nonsmall Cell Lung Cancer.
Munaweera I; Shi Y; Koneru B; Saez R; Aliev A; Di Pasqua AJ; Balkus KJ
Mol Pharm; 2015 Oct; 12(10):3588-96. PubMed ID: 26325115
[TBL] [Abstract][Full Text] [Related]
46. Blood and urine analyses after radioembolization of liver malignancies with [
Bakker RC; de Roos R; Ververs FFT; Lam MGEH; van der Lee MK; Zonnenberg BA; Krijger GC
Nucl Med Biol; 2019 Apr; 71():11-18. PubMed ID: 31108463
[TBL] [Abstract][Full Text] [Related]
47. Feasibility of Affibody-Based Bioorthogonal Chemistry-Mediated Radionuclide Pretargeting.
Altai M; Perols A; Tsourma M; Mitran B; Honarvar H; Robillard M; Rossin R; ten Hoeve W; Lubberink M; Orlova A; Karlström AE; Tolmachev V
J Nucl Med; 2016 Mar; 57(3):431-6. PubMed ID: 26659353
[TBL] [Abstract][Full Text] [Related]
48. Identifying aberrant hepatic arteries prior to intra-arterial radioembolization.
van den Hoven AF; Smits ML; de Keizer B; van Leeuwen MS; van den Bosch MA; Lam MG
Cardiovasc Intervent Radiol; 2014 Dec; 37(6):1482-93. PubMed ID: 24469409
[TBL] [Abstract][Full Text] [Related]
49. 3D inpatient dose reconstruction from the PET-CT imaging of 90Y microspheres for metastatic cancer to the liver: feasibility study.
Fourkal E; Veltchev I; Lin M; Koren S; Meyer J; Doss M; Yu JQ
Med Phys; 2013 Aug; 40(8):081702. PubMed ID: 23927299
[TBL] [Abstract][Full Text] [Related]
50. Neutron-activated holmium-166-poly (L-lactic acid) microspheres: a potential agent for the internal radiation therapy of hepatic tumors.
Mumper RJ; Ryo UY; Jay M
J Nucl Med; 1991 Nov; 32(11):2139-43. PubMed ID: 1941151
[TBL] [Abstract][Full Text] [Related]
51. Phase II study of transarterial holmium-166-chitosan complex treatment in patients with a single, large hepatocellular carcinoma.
Sohn JH; Choi HJ; Lee JT; Lee JD; Kim JH; Moon YM; Park K; Park KB; Kim E; Yoo NC
Oncology; 2009; 76(1):1-9. PubMed ID: 19018149
[TBL] [Abstract][Full Text] [Related]
52. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
[TBL] [Abstract][Full Text] [Related]
53. Microsphere localization and dose quantification using positron emission tomography/CT following hepatic intraarterial radioembolization with yttrium-90 in patients with advanced hepatocellular carcinoma.
Lea WB; Tapp KN; Tann M; Hutchins GD; Fletcher JW; Johnson MS
J Vasc Interv Radiol; 2014 Oct; 25(10):1595-603. PubMed ID: 25156647
[TBL] [Abstract][Full Text] [Related]
54. Radiation emission from patients treated with holmium-166 radioembolization.
Prince JF; Smits ML; Krijger GC; Zonnenberg BA; van den Bosch MA; Nijsen JF; Lam MG
J Vasc Interv Radiol; 2014 Dec; 25(12):1956-1963.e1. PubMed ID: 25311966
[TBL] [Abstract][Full Text] [Related]
55. Radioactive microspheres in therapeutics.
Sinha VR; Goyel V; Trehan A
Pharmazie; 2004 Jun; 59(6):419-26. PubMed ID: 15248454
[TBL] [Abstract][Full Text] [Related]
56. Prospective Evaluation of (99m)Tc-sestamibi SPECT/CT for the Diagnosis of Renal Oncocytomas and Hybrid Oncocytic/Chromophobe Tumors.
Gorin MA; Rowe SP; Baras AS; Solnes LB; Ball MW; Pierorazio PM; Pavlovich CP; Epstein JI; Javadi MS; Allaf ME
Eur Urol; 2016 Mar; 69(3):413-6. PubMed ID: 26386607
[TBL] [Abstract][Full Text] [Related]
57. Evaluation Efficacy of Rhenium-188-Loaded Micro-particles for Radiotherapy in a Mouse Model of Hepatocellular Carcinoma.
Shih YH; Peng CL; Weng MF; Chiang PF; Luo TY; Lin XZ
Mol Pharm; 2019 Mar; 16(3):1083-1091. PubMed ID: 30638389
[TBL] [Abstract][Full Text] [Related]
58. Whole-body PET/CT evaluation of tumor perfusion using generator-based 62Cu-ethylglyoxal bis(thiosemicarbazonato)copper(II): validation by direct comparison to 15O-water in metastatic renal cell carcinoma.
Fletcher JW; Logan TF; Eitel JA; Mathias CJ; Ng Y; Lacy JL; Hutchins GD; Green MA
J Nucl Med; 2015 Jan; 56(1):56-62. PubMed ID: 25525184
[TBL] [Abstract][Full Text] [Related]
59. Quantitative Imaging Biomarkers for
Schobert I; Chapiro J; Nezami N; Hamm CA; Gebauer B; Lin M; Pollak J; Saperstein L; Schlachter T; Savic LJ
J Nucl Med; 2019 Aug; 60(8):1066-1072. PubMed ID: 30655331
[TBL] [Abstract][Full Text] [Related]
60. MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with
Ku A; Chan C; Aghevlian S; Cai Z; Cescon D; Bratman SV; Ailles L; Hedley DW; Reilly RM
Mol Pharm; 2019 Aug; 16(8):3559-3568. PubMed ID: 31242384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
